TG Therapeutics (NASDAQ:TGTX) Downgraded by BidaskClub

BidaskClub downgraded shares of TG Therapeutics (NASDAQ:TGTX) from a hold rating to a sell rating in a research report report published on Thursday, BidAskClub reports.

Several other brokerages also recently issued reports on TGTX. Cantor Fitzgerald reissued a buy rating and issued a $17.00 price objective on shares of TG Therapeutics in a research note on Monday, May 13th. ValuEngine raised TG Therapeutics from a hold rating to a buy rating in a research note on Thursday, August 1st. B. Riley reissued a buy rating on shares of TG Therapeutics in a research note on Tuesday, June 11th. Finally, Zacks Investment Research raised TG Therapeutics from a sell rating to a hold rating in a research note on Thursday, August 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $14.07.

Shares of NASDAQ TGTX opened at $6.01 on Thursday. TG Therapeutics has a 12 month low of $3.32 and a 12 month high of $12.90. The company has a quick ratio of 1.69, a current ratio of 1.69 and a debt-to-equity ratio of 2.77. The business has a fifty day simple moving average of $7.40 and a 200-day simple moving average of $7.10.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Friday, August 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.01. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 496.99% and a negative net margin of 99,488.13%. Equities research analysts forecast that TG Therapeutics will post -1.53 EPS for the current year.

In other news, CFO Sean A. Power sold 17,654 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $8.47, for a total transaction of $149,529.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael S. Weiss purchased 50,000 shares of the business’s stock in a transaction dated Wednesday, June 26th. The shares were purchased at an average cost of $7.04 per share, with a total value of $352,000.00. The disclosure for this purchase can be found here. 14.20% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC raised its stake in shares of TG Therapeutics by 5.0% during the 2nd quarter. SG Americas Securities LLC now owns 30,858 shares of the biopharmaceutical company’s stock worth $267,000 after purchasing an additional 1,481 shares in the last quarter. Aperio Group LLC purchased a new stake in shares of TG Therapeutics during the 2nd quarter worth about $32,000. Parametric Portfolio Associates LLC raised its stake in shares of TG Therapeutics by 45.4% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 21,152 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 6,609 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of TG Therapeutics by 10.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 71,312 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 6,812 shares in the last quarter. Finally, Bank of Montreal Can increased its holdings in shares of TG Therapeutics by 1,119.0% during the 2nd quarter. Bank of Montreal Can now owns 8,143 shares of the biopharmaceutical company’s stock valued at $70,000 after acquiring an additional 7,475 shares during the last quarter. 53.17% of the stock is owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Featured Article: What are the benefits of a portfolio tracker?

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.